Jacob Aelion

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Placebo Controlled

Top Venues

Rheumatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)